UPF 648

Pricing Availability Delivery Time Qty
Cat.No. 4926 - UPF 648 | C11H8Cl2O3 | CAS No. 213400-34-1
Description: Potent kynurenine 3-monooxygenase (KMO) inhibitor
Chemical Name: (1S,2S)-2-(3,4-Dichlorobenzoyl)cyclopropanecarboxylic acid
Purity: ≥98% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC50 = 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila model of Huntington's disease.

Technical Data

M. Wt 259.09
Formula C11H8Cl2O3
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 213400-34-1
PubChem ID 9859947
InChI Key ZBRKMOHDGFGXLN-BQBZGAKWSA-N
Smiles [H][C@]1([C@@H]([C@](O)=O)C1)C(C2=CC=C(Cl)C(Cl)=C2)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
ethanol 25.91 100

Preparing Stock Solutions

The following data is based on the product molecular weight 259.09. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.86 mL 19.3 mL 38.6 mL
5 mM 0.77 mL 3.86 mL 7.72 mL
10 mM 0.39 mL 1.93 mL 3.86 mL
50 mM 0.08 mL 0.39 mL 0.77 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Ceresoli-Borroni et al (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J.Neurosci.Res. 85 845 PMID: 17279543

Amaral et al (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496 382 PMID: 23575632

Amori et al (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J.Neurochem. 109 316 PMID: 19226371

Campesan et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr.Biol. 21 961 PMID: 21636279


If you know of a relevant reference for UPF 648, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Kynurenine 3-monooxygenase Inhibitors

Keywords: UPF 648, supplier, UPF648, potent, kynurenine, 3-monooxygenase, 3-hydroxylase, KMO, inhibitors, inhibits, huntington's, disease, KYNA, 3-hk, QUIN, neuroprotective, Hydroxylases, KMO, KMO, Tocris Bioscience

Citations for UPF 648

Citations are publications that use Tocris products.

Currently there are no citations for UPF 648. Do you know of a great paper that uses UPF 648 from Tocris? If so please let us know.

UPF 648 Reviews

Average Rating:

(Based on 0 Reviews)


1 Star
0%
2 Star
0%
3 Star
0%
4 Star
0%
5 Star
0%

Have you used UPF 648?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.


Literature in this Area

Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Multiple Sclerosis

Multiple Sclerosis Poster

Multiple sclerosis (MS) is an autoimmune disease that is characterized by focal demyelination and axon degeneration in the central nervous system. This poster summarizes the neurobiology and current therapies of MS.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.